Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Pfizer, Medivation Halt Alzheimer’s Pact

by Lisa M. Jarvis
January 23, 2012 | A version of this story appeared in Volume 90, Issue 4

Pfizer and Medivation are ending their collaboration for the Alzheimer’s disease drug candidate dimebon and discontinuing development of the compound. The news comes after a Phase III study showed that giving the drug in combination with Pfizer’s Aricept did not improve cognitive ability or daily functioning in people with Alzheimer’s disease. In 2008, Pfizer paid $225 million for access to dimebon and agreed to pay Medivation upward of $500 million as the drug candidate progressed. The big pharma firm also took on 60% of the development expenses for the failed drug.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.